Too-low iron doses and too many dropouts in negative iron trial?

Journal of Clinical Oncology

Volumn 29, Issue 17, 2011, Pages

  Aapro, Matti ^a   Beguin, Yves ^b   Birgegård, Gunnar ^c   Gascón, Pere ^d   Hedenus, Michael ^e   Österborg, Anders ^f  

^a CLINIQUE DE GENOLIER   (Switzerland)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c UPPSALA UNIVERSITY   (Sweden)

^d HOSPITAL CLÍNIC   (Spain)

^e SUNDSVALL HOSPITAL   (Sweden)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; ANTINEOPLASTIC AGENT; FERRIC GLUCONATE; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; TRANSFERRIN;

ANEMIA; DRUG WITHDRAWAL; ERYTHROPOIESIS; HEMATOPOIESIS; HUMAN; LETTER; OXIDATIVE STRESS; PRIORITY JOURNAL; SUPPLEMENTATION; UNSPECIFIED SIDE EFFECT;

ANEMIA; ANTINEOPLASTIC AGENTS; FERRIC COMPOUNDS; HUMANS; IRON; PATIENT DROPOUTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRANSFERRIN;

EID: 79959271202     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.35.3219     Document Type: Letter

References (14)

1. Steensma DP, Sloan JA, Dakhil SR, et al: Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia. J Clin Oncol 29:97-105, 2011
2. Auerbach M, Ballard H, Trout JR, et al: Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: A multicenter, open-label, randomized trial. J Clin Oncol 22:1301-1307, 2004 (Pubitemid 41079845)
3. Auerbach M, Silberstein PT, Webb RT, et al: Darbepoetin alfa 300 or 500 ug once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. Am J Hematol 85:655-663, 2010
4. Bastit L, Vandebroek A, Altintas S, et al: Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol 26:1611-1618, 2008
5. Hedenus M, Birgegård G, Näsman P, et al: Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: A randomized multicenter study. Leukemia 21:627-632, 2007 (Pubitemid 46444544)
6. Henry DH, Dahl NV, Auerbach M, et al: Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 12:231-242, 2007
7. Pedrazzoli P, Farris A, Del Prete S, et al: Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol 26:1619-1625, 2008
8. Beguin Y, Maertens J, De Prijck B, et al: Darbepoetin-alfa and I.V. iron administration after autologous hematopoietic stem cell transplantation: A prospective randomized multicenter trial. Blood 112, 2008 (abstr 54)
9. Bellet RE, Ghazal H, Flam M, et al: A phase III randomized controlled study comparing iron sucrose intravenously (IV) to no iron treatment of anemia in cancer patients undergoing chemotherapy and erythropoietin stimulating agent (ESA) therapy. J Clin Oncol 25:519S, 2007 (abstr 9109)
10. Auerbach M: Intravenous iron failed to improve erythropoietic response in patients with chemotherapy-induced anemia. HemOnc Today, 2010. http://www.hemonctoday.com/article.aspx?rid=78461
11. sanofi-aventis: Ferrlecit prescribing information. http://products. sanofi-aventis.us/ferrlecit/ferrlecit.html
12. Gafter-Gvili A, Rozen-Zvi B, Vidal L, et al: Intravenous iron supplementation for the treatment of cancer-related anemia: Systematic review and meta-analysis. Blood 116:21, 2010 (abstr 4249)
13. Mhaskar R, Wao H, Kumar A, et al: Role of iron supplementation to erythropoiesis stimulating agents in the management of chemotherapy-induced anemia in cancer patients: A systematic review and meta-analysis. Blood 116:21, 2010 (abstr 2055)
14. Steensma D, Dakhil SR, Novotny PJ, et al: A phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia: A study of the Mayo Clinic Cancer Research Consortium (MCCRC). Blood 114:22, 2009 (abstr 3008)